| ≤29 years | 30–34 years | 35–39 years | 40–44 years | ≥45 years | |
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |
| 2007 | 11% | 29% | 42% | 16% | 1% |
| 2008 | 11% | 30% | 40% | 18% | 1% |
| 2009 | 11% | 29% | 41% | 18% | 1% |
| 2010 | 11% | 29% | 40% | 18% | 1% |
| 2011 | 10% | 30% | 39% | 19% | 2% |
| 2012 | 9% | 30% | 40% | 19% | 2% |
| 2013 | 9% | 30% | 39% | 20% | 2% |
| 2014 | 9% | 28% | 41% | 20% | 1% |
| 2015 | 9% | 30% | 41% | 20% | 1% |
| 2016 | 9% | 29% | 42% | 18% | 1% |
| 2017 | 10% | 32% | 40% | 17% | 1% |
| 2018 | 10% | 31% | 40% | 18% | 1% |
| 2019 | 9% | 30% | 40% | 20% | 1% |
| 2020 | 9% | 31% | 40% | 20% | 1% |
| 2021 | 9% | 31% | 40% | 19% | 1% |
| 2022 | 9% | 30% | 41% | 20% | 1% |
| ≤29 years | 30–34 years | 35–39 years | 40–44 years | ≥45 years |
Start of treatment: Treatment begins with hormone stimulation in the woman, designed to promote the maturation of oocytes. ● All couples are included who started treatment in the year in question.
Source: FIVNAT/SFSO